Cyolo Security Announces Partnership with TD SYNNEX
26.3.2024 15:30:00 EET | Business Wire | Press release
Cyolo, the access company for the industrial enterprise, today announced a new partnership with TD SYNNEX, a leading global distributor and solutions aggregator for the IT ecosystem. The powerful combination of TD SYNNEX’s solution aggregation capabilities and Cyolo’s highly disruptive, distributed secure remote access platform will lead partners to new service lines of revenue. The partnership empowers TD SYNNEX and Cyolo partners to tap into the increased enterprise demand of Secure Remote Access in operational technology (OT), critical infrastructure, cyber physical environments, and their corresponding buying centers.
The partnership with TD SYNNEX serves as the cornerstone of the Cyolo PRO (Privilege Remote Operations) launch. The recently launched Cyolo PRO Platform allows service providers, integrators, OT, IT personnel and other third parties to securely access and safely operate applications, devices and systems in the most critical environments. Cyolo PRO takes secure remote access to new levels with its distributed architecture and its converged security stack capabilities. Cyolo is cloud routed and cloud managed without being cloud hosted. Unlike current technologies such as VPN and SASE that provide users with full access to the network, Cyolo PRO enables secure and privileged access by connecting robustly verified identities to applications with persistent authorization.
“The strategic nature of our TD SYNNEX relationship is a pivotal step in realizing our commitment to delivering future-ready, safe and secure privilege access solutions to the massive industrial market,” said Cyolo’s EVP Corporate Development and OT GM Joe O’Donnell. “Through this collaboration, TD SYNNEX’s partners can bring Cyolo PRO to a broader range of OT, IT and Cyber Physical stakeholders. This increases safety, security and accelerates operational agility. The solution’s capability to seamlessly fit into existing architectures without extensive change management processes is critical in OT environments, as even the slightest network and security change can yield significant consequences.”
This global partnership enables thousands of TD SYNNEX integrators, VARs, MSSPs and Carriers to provide next generation SRA/RPAM (Remote Privilege Access Management) services to their respective customers. Cyolo PRO enables TD SYNNEX partners to address the fast-growing OT and Cyber Physical markets by focusing on crucial elements that increase their clients’ operational agility, improves customers’ security and providing safe yet swift implementations with the lowest cost of change.
"TD SYNNEX is committed to uniting IT solutions that deliver business outcomes today and unlock growth for the future," said Cheryl Day, VP Vendor Acquisition and Global Solutions at TD SYNNEX. "With Cyolo added to our vast portfolio of vendor partners, we're able to enrich the breadth and depth of our offerings so customers can do great things with technology."
To learn more about Cyolo PRO, please visit: https://cyolo.io/product
About Cyolo
Cyolo replaces current SRA implementations with next gen privileged remote operations by connecting verified identities directly to applications with continuous authorization throughout the connection. Purpose-built for deployment in every type of environment, Cyolo PRO combines multiple Remote Privilege Access Management (RPAM) security functions required to mitigate high-risk access, including zero-trust access for users and devices, MFA for the last mile, IdP capabilities, credentials vault, secure file transfer, supervised access, session recording, and much more into a single, cost-effective, easy-to-deploy, and user-friendly platform. For more information visit cyolo.io or follow us on LinkedIn and X.
About TD SYNNEX
TD SYNNEX (NYSE: SNX) is a leading global distributor and solutions aggregator for the IT ecosystem. We’re an innovative partner helping more than 150,000 customers in 100+ countries to maximize the value of technology investments, demonstrate business outcomes and unlock growth opportunities. Headquartered in Clearwater, Florida, and Fremont, California, TD SYNNEX’s 23,000 co-workers are dedicated to uniting compelling IT products, services and solutions from 2,500+ best-in-class technology vendors. Our edge-to-cloud portfolio is anchored in some of the highest-growth technology segments including cloud, cybersecurity, big data/analytics, AI, IoT, mobility and everything as a service. TD SYNNEX is committed to serving customers and communities, and we believe we can have a positive impact on our people and our planet, intentionally acting as a respected corporate citizen. We aspire to be a diverse and inclusive employer of choice for talent across the IT ecosystem. For more information, visit www.TDSYNNEX.com, follow our newsroom or follow us on LinkedIn, Facebook and Instagram.
Copyright 2024 TD SYNNEX Corporation. All rights reserved. TD SYNNEX, the TD SYNNEX Logo, and all other TD SYNNEX company, product and services names and slogans are trademarks of TD SYNNEX Corporation. Other names and trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326860005/en/
Contact information
Cyolo Media Inquiries
10Fold
cyolo@10Fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
